Drugs / Ad35-GRIN
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01705990 | Mar 2013 → Mar 2015 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
| Phase 1 | NCT01264445 | Feb 2011 → Nov 2012 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
| Phase 1 | NCT00851383 | Mar 2009 → Aug 2011 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02099994 | Mar 2014 → Aug 2015 | AIDS | University of Oxford | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad35-GRIN | “non-replicating adenovirus 35 expressing clade A Gag, RT, Int and Nef (Ad35-GRIN)” PMID 25961283 ↗ May 2015 |
| Modality | Vaccine | “Ad35-GRIN HIV vaccine” NCT00851383 ↗ |
| Route | Intramuscular | “Ad35-GRIN/ENV (Ad35-GRIN and Ad35-ENV mixed in the same vial in equal proportions) or Ad35-GRIN was administered intramuscularly at 0 and 6 months.” PMID 22870265 ↗ Aug 2012 |